Cosmetic News In Brief: Unilever Nabs Living Proof; TINA.org’s ‘Naughty’ List; More

Unilever will add Living Proof hair care to its prestige portfolio through an acquisition expected to close in the 2017 first quarter; Memebox raises $60m in new funding; WEN and The Honest Company make nonprofit Truth In Advertising’s 2016 “naughty” list. More cosmetics news in brief.

The Anglo-Dutch consumer-goods giant continues its 2016 buying spree with the acquisition of Living Proof, Inc. for an undisclosed sum, adding to its portfolio a range of premium, problem-solving hair-care products based on “science and patented technology originating from MIT.” (Also see "Living Proof Takes An Outside Approach To Solving Everyday Hair Issues" - HBW Insight, 5 November, 2012.) Founded in 2005 by Massachusetts Institute of Technology professor Robert Langer and Jon Flint of private-equity firm Polaris Venture Partners, Living Proof will join brands including Dermalogica, Kate Somerville, Murad and REN in Unilever’s prestige lineup. “The prestige hair retail market is very attractive and offers significant potential for growth,” says Unilever’s Personal Care President Alan Jope, touting Living Proof’s “compelling product result demonstrations and influencer-driven marketing.” The deal, expected to close in the first quarter of 2017, follows the firm’s purchase of Dollar Shave Club in July and Seventh Generation in September, among other pickups of late. The firm also was rumored to be in talks with The Honest Company prior to recent transactions that have made a bid for Honest less likely in analysts’ eyes. (Also see "They’re Just Like Us! Honest Celeb Brand’s Illusory Persona Fading" - HBW Insight, 30 November, 2016.)

Direct-to-consumer startup Memebox, with deep roots in Korean beauty, will use $60m of funding raised through a Series C extension...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Deals

Nancy Tests Arc AI Editor

 
• By 

Curve Biosciences has developed a "Whole-Body Intelligence" platform using cfDNA from blood to monitor chronic diseases, starting with the liver. Focused on liver cirrhosis and MASH, the company aims to aid in treatment decisions and plans to expand into monitoring other organs.

HI-Beauty (Free-2): How the Future of Medicine Will Revolve Around Our Gut

 
• By 

The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Commonly Prescribed Medications for Attention Deficit Hyperactivity Disorder)

 
• By 

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.

L’Oreal Acquires 10% Stake, Plans R&D Collaboration With Galderma

 

L’Oréal and Galderma have signed a memorandum of understanding to collaborate on complementary research projects to discover ‘new avenues and accelerate innovation’ in the field of dermatology. L’Oreal has arranged to purchase a 10% stake in its partner.

More from Business

HI-Beauty (Free-2): How the Future of Medicine Will Revolve Around Our Gut

 
• By 

The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Commonly Prescribed Medications for Attention Deficit Hyperactivity Disorder)

 
• By 

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.